Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 513943, 7 pages
Review Article

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion

1Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener Street 34, 50931 Cologne, Germany
2Institute of Neuropathology, University of Erlangen, Germany
3Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany
4Pharmaceutical Institute, University of Würzburg, 97074 Würzburg, Germany
5Department of Neurology, University of Bonn, 53105 Bonn, Germany

Received 21 April 2008; Accepted 2 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Sebastian Seufert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Today, there is increasing evidence that PPAR agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block the motility and invasiveness of glioma cells and other highly migratory tumor entities. However, the mechanism(s) by which PPAR activators mediate their antimigratory and anti-invasive properties remains elusive. This letter gives a short review on the debate and adds to the current knowledge by applying a PPAR inactive derivative of the TDZ troglitazone (Rezulin) which potently counteracts experimental glioma progression in a PPAR independent manner.